Pharmacokinetics of ciprofloxacin in young (healthy volunteers) and elderly patients, and concentrations in prostatic fluid, seminal fluid, and prostatic adenoma tissue following intravenous administration by Naber, K. G. et al.
Brief Report: Pharmacokinetics of 
Ciprofloxacin in Young (healthy volunteers) and 
Elderly Patients, and Concentrations in 
Prostatic Fluid, Seminal Fluid, and Prostatic 
Adenoma Tissue following Intravenous 
Administration 
KURT 6. NABER, M.D. Straubing, federal Rep&//c of Germany FRITZ SORGEL, Ph.D. Nijrnberg, Federal Repubiic of Germany 
FRIEDER KEES, Ph.D. Regensberg, Federal Republic of Germany ULRICH JAEHDE Niirnberg, Federal Republic of Germany 
HARALD SCHUMACHER, M.D. Straubing, Federal Repubkc of Germany 
C iprofloxacin has a broad antibacterial spectrum with favorable pharmacokinetic properties and 
can be administered orally as well as parenterally. 
Therefore, it has been used widely in the treatment of 
complicated nosocomial urinary tract infections and 
demonstrated to be suitable for therapy of bacterial 
prostatitis and for perioperative prophylaxis in urolo- 
gic surgery. 
In this study, the pharmacokinetics of ciprofloxacin 
after intravenous administration in younger volun- 
teers and elderly patients were compared, and con- 
centrations in prostatic and seminal fluid and in pros- 
tatic adenoma tissue following intravenous adminis- 
tration were determined. 
MATERIALS AND METHODS 
Study in Volunteers 
Two groups of healthy male volunteers took part in 
the study. 
Group 1 
Twelve volunteers aged 19 to 33 years (median, 27 
years) with a body weight of 67 to 83 kg (median, 79 
kg) received a 30-minute intravenous infusion of 200 
mg ciprofloxacin and a bolus intravenous injection of 
2.534 g ioxitalamic acid (IOTA) (5 ml Telebrix 300R, 
Byk Gulden, Konstanz). Venous blood samples were 
taken before, during (15 minutes), at the end of infu- 
sion, at 10, 29, 30, 45, 60, and 90 minutes, and at two, 
three, four, six, eight? 10, 12, and 24 hours after infu- 
sion. Prostatic secretion was obtained by massage of 
the prostate at 0.5, 1.0, 1.5 and 2.0 hours after the 
infusion (three subjects at each time). Urine was col- 
lected in portions: zero to four, four to eight, eight to 
12, 12 to 24 hours. 
Group 2 
Twelve volunteers aged 25 to 33 years (median, 27 
years) with a body weight of 68 to 84 kg (median, 76 
kg) received an intravenous infusion of 200 mg cipro- 
floxacin and a bolus intravenous injection of 2.534 g 
IOTA. Group 2 was divided into three subgroups of 
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I I 
four persons each: group 2a received a 30-minute in- 
travenous infusion of ciprofloxacin and an intravenous 
bolus injection of IOTA. Prostatic and seminal fluid 
(split ejaculate) were obtained four hours after the in- 
fusion; group 2b received an intravenous injection of 
IOTA, an intravenous bolus injection of IOTA, and 
intravenous injection of 50 mg ciprofloxacin followed 
by a constant infusion of 150 mg ciprofloxacin over 
four hours. Prostatic and seminal fluid (split ejaculate) 
were obtained at the end of the infusion; group 2c re- 
ceived a 30-minute intravenous infusion of ciprofloxa- 
tin and eight hours after the infusion an intravenous 
bolus injection of IOTA. Prostatic and seminal fluid 
(split ejaculate) were obtained at 12 hours after the 
infusion. 
In groups 2a and 2b, volunteers were not allowed to 
pass urine prior to sampling prostatic and seminal 
fluid. In group 2c, volunteers voided urine about one 
hour before sampling of prostatic and seminal fluid. 
Study in Patients 
There were two groups of male patients: group A 
and group B. 
Group A 
Group A consisted of 14 patients undergoing trans- 
urethral resection of the prostate. They were aged 57 
to 84 years (median, 74 years) with a body weight of 
50 to 80 kg (median, 72 kg), and a serum creatinine 
level of 0.8 to 1.9 mg/dl (median, 1.0 mg/dl). The pa- 
tients received a 30-minute intravenous infusion of 200 
mg ciprofloxacin and a bolus intravenous injection of 
2.534 g IOTA. Venous blood samples were taken be- 
fore, during (15 minutes), at the end of the infusion, at 
10, 20: 30, 45, and 90 minutes, and at two, three, four, 
six? eight, and 10 hours after the infusion. Prostatic 
fluid and adenoma tissue samples were obtained 1.0 to 
2.5 hours after infusion. 
Group B 
Three patients undergoing transvesical enucleation 
of the prostate, aged 77, 81, and 85 years with body 
weights of 61, ‘70, and 86 kg and with serum creatinine 
levels of 1.0, 1.0, and 2.9 mg/dl, respectively, received 
a 30-minute intravenous infusion of 200 mg ciprofloxa- 
tin and a bolus intravenous injection of 2.534 g IOTA. 
Venous blood and tissue samples were taken 16 to 18 
hours after the end of the infusion. Prostatic secretion 
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Fi, gure 1. Mean plasma concentrations (cont.) of ciprofloxacin following a 30. 
minute intravenous infusion of 200 mg in 12 healthy volunteers and 11 elderly 
patients. 
was obtained by manually exprimating tissue slices 
weighing about 1 to 3 g. 
Concentrations of ciprofloxacin and IOTA were de- 
termined by high-performance liquid chromatographic 
methods [l]. Tissue samples were homogenized by an 
ultra turrax (IRA, Lauffen, Federal Republic of Ger- 
many). Pharmacokinetic parameters were calculated 
according to a model independent method. Statisti- 
cally significant differences between the groups of vol- 
unteers (group 1) and patients (group A) were calcu- 
lated using the Mann-Whitney rank sum test. A p 
value of less than 0.05 was considered significant. 
RESULTS 
Pharmacokinetics in Volunteers and Elderly Patients 
Figure 1 shows the mean concentrations of cipro- 
floxacin in volunteers (group 1) and elderly patients 
(group A). In Table I the pharmacokinetic parameters 
of ciprofloxacin and IOTA for these two groups are 
listed. Elderly patients had higher maximal concen- 
trations (p <0.05), a larger area under the curve 
(p <O.OOl), a smaller volume of distribution during 
steady state (p <0.05) and during terminal elimination 
(p <O.OOl), and a smaller total clearance (p <O.OOl) as 
compared with volunteers. The higher maximal con- 
centration and area under the curve can be explained 
partly because the mean body weight of the group of 
elderly patients (69.5 f 9.1 kg) was lower than that of 
volunteers (76.0 2 4.7 kg). There was, however, also 
a significantly smaller volume of distribution per body 
weight during terminal elimination (p ~0.05) and dur- 
ing steady-state (p = 0.05) in elderly patients as com- 
pared with volunteers. The reduction of total clear- 
ance of IOTA, which is almost exclusively excreted by 
glomerular filtration, is explained by reduction of 
renal function in elderly patients leading to prolonga- 
tion of half-life of IOTA. In contrast, the half-life of 
ciprofloxacin increased only slightly, but not signifi- 
cantly in elderly patients. 
Concentrations in Prostatic and Seminal Fluid and in 
Prostatic Adenoma Tissue 
The concentrations of ciprofloxacin in prostatic and 
seminal fluid of volunteers are listed in Table II. One 
subject of group 1 (0.5 to 2.0 hours) and four subjects 
of group 2c (12 hours) showed IOTA fluid-to-plasma 
ratios far above unity and were therefore excluded 
from analysis due to urinary contamination. In the 18 
remaining subjects, showing fluid-to-plasma ratios of 
0.1 as maximum, the median concentrations of cipro- 
floxacin in prostatic fluid were in group 1 (0.5 to 2.0 
hours) 0.16 mg/liter and in group 2 (four hours) 0.08 
mg/liter with fluid-to-plasma ratios of 0.26 and 0.18, 
respectively. The median concentrations in seminal 
fluid (fraction l/fraction 2) after four hours (12 hours) 
were 2.5312.53 mg/liter (0.61/0.‘70 mg/liter) with 
plasma-to-fluid ratios of 5.8D.l (7.919.4). 
The concentrations of prostatic fluid and adenoma 
tissue of patients are listed in Table III. Prostatic 
fluid results of two patients had to be excluded be- 
cause of urinary contamination (prostatic fluid/plasma 
ratio of ioxitalamic acid was greater than 1 mg/liter). 
In the remaining seven patients of group A (1.0 to 2.5 
hours)/group B (16 to 18 hours), the median concentra- 
tions were 0.62iO.06 mg/liter with a fluid-to-plasma 
ratio of 0.4810.86. The median tissue concentration in 
group AIB was 1.87/0.13 pglg with tissue-to-fluid ratio 
of 2.4511.86. 
TABLE I 
Pharmacokinetic Parameters (model independent estimation) in 12 Young Volunteers and in 11 Elderly Patients after a 30. 
Minute Intravenous Infusion of 200 mg of Ciprofloxacin and after an Intravenous Bolus Injection of 2.534 g loxitalamic Acid* 
C,,, (mgiliter) 
AUC (rng x h/liter) 
tit2 (hours) 
VdB (liters] 
V,,, (liters) 
Cl,, (ml/minute) 
Cl,, (ml/minute) 
Volunteers* Elderly Patientst 
Ciprofloxacin IOTA 
3.43 2 0.64+ 
5.37 i 0.728 
3.58 i 0.54 
194 + 27 
157 i $ 25 
632 2 75s 
328 k 96 
185~ 19 
:ii : i%t. 
21.6 i 4.1$ 
17.2 F 2.3 
111 ? 125 
112 It- 12 
Ciprofloxacin 
4.15 i 0.79+ 
8.79 k 2.73 
4.31 t 1.38 
143 * 29 ! 
115 ?E 29 
407 ~~04g 
IOTA 
192 2 26 
595 t 181 
2.97 c 0.76 P
18.5 + 2.Ot 
16.5 i 1.9 
76.5 2.2s 
V,,IBW (liters/kg) 2.52 ? 0.32t 0.28 c 0.05 2.09 -t 0.54+ 0.27 r 0.05 
!&,/SW (liters/kg) 1.94 i 0.29f 0.22 Ii 0.03 1.69 + 0.52+ 0.24 i 0.04 
CI,,,/BW (ml/minute kg) 8.25 5 1.711 1.45 t 0.15t 6.02 t I.9011 1.12 + 0.31f 
ITA = ioxitalamic acid; C,,, = maximal concentrations; AUC = area under the curve; ti,* = half-life; V,,, = volume distributron during termrnal elimination; V,,, = volume of distribl 
In during steady-state; Cl,,, = total clearance; Cl,,, = renal clearance; BW = body weight; ND = not done. 
Mean body weight 76.9 2 4.7 kg. 
Vlean body weight 69.5 ? 9.1 kg. 
I 5 0.05; 5 p ~0.01; /Ip <O.Ol; (Mann-Whitney rank sum test) between the groups of volunteers and elderly patients. 
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TABLE II 
Concentrations of Ciprofloxacin in Plasma and Prostatic and Seminal Fluid (split ejaculate) of Volunteers after Intravenous 
Infusion of 200 mg Ciprofloxacin 
Time (hours) Number of Subjects 
Plasma Level (mg/liter) 
Median Range 
Fluid Level (mg/liter) 
Median Range 
Plasma Level (mplliter) 
Median Range 
0.5-2 10* 0.67 0.45-1.12 
4 8 0.44 0.35-0.58 
1; 4” 0.44 09 0.06-0.10 35 58
1: i 0.44 09 0.35-0.58 06 10
PfOSMiC 
0.16 0.10-0.50 0.26 0.15-0.53 
0.08 0.03-0.19 0.18 0.05-0.33 
Sem/na/ 
(fraction 1) 
0.61 2,53 0.54-1.38 1.75 4.11 5.8 7 9 4.0-8.6 6.7-13.8 
(fraction 2) 
2.53 0 70 0.44-1.37 1.75 4.14 9.4 7.1 3.0-10.6 4 9 31 
One was excluded from evaluation because of urinary contamination (prostatic fluid/plasma ratio of ioxrtalamic acid was greater than 1). 
TABLE Ill 
Concentrations of Ciprofloxacin in Plasma, Prostatic Fluid, and Adenoma Tissue in 14 Patients (group A) Undergoing 
Transurethral Resection and in three Patients (group B) Undergoing Transvesical Enucleation of Prostatic Adenoma after 
30.Minute Intravenous Infusion of 200 mg Ciprofloxacin 
Group 
A 
8 
Time (hours) 
:.Ki 
Number of Subjects 
7* 
3 
Plasma Prostatic Material 
h&d hdk) Prostatic Material/Plasma 
Median Range Median Range Median Range 
Prostatic hid 
0.82 0.55-1.54 0.62 0.14-1.01 0.48 0.21-1.20 
0.09 0.07,0.23 0.06 0.04,0.27 0.86 0.44,1.17 
Prosfatic Tissue .~~ ..~ 
! Kti 14 3 0.09 81 0.55-1.54 07,0 23 0.13 1.87 1.02-5.81 0 1 ,0 47 1.86 2.45 1.41-5.43 33,2 04
*Two were excluded from evaluation because of urinary contamination (prostatic flurd/plasma ratio of ioxitalamic acid was greater than 1 mglliter). 
COMMENTS 
After a 30-minute intravenous infusion of 200 mg 
ciprofloxacin, plasma concentrations can exceed 3 mg/ 
liter. Because of its large apparent volume of distribu- 
tion, good tissue penetration can be assumed. The 
ciprofloxacin volume of distribution during steady- 
state (p ~0.05) and during terminal elimination 
(p ~0.001) are significantly smaller in elderly patients 
than in volunteers. However, this was not true for 
IOTA, which distributes only into the extracellular 
space. The terminal half-life between younger volun- 
teers and elderly patients was not significantly differ- 
ent, despite significantly (p ~0.001) lower total 
plasma clearance per body weight in patients. Accord- 
ing to our studies, dosage adjustments in elderly pa- 
tients are not necessary despite expected reduction of 
renal function in this age group, which can be demon- 
strated by the significantly (p CO.001) smaller total 
plasma clearance of IOTA. 
In contrast to other studies [2,3], concentrations 
determined in prostatic fluid in healthy young volun- 
teers and in patients did not exceed plasma concentra- 
tions, if urinary contamination can be identified by 
means of IOTA. As has been shown by other authors, 
the concentrations in seminal fluid [3] and in prostatic 
tissue [4,5] exceeded plasma concentrations by sev- 
eral-fold. Due to the broad spectrum, the favorable 
pharmacokinetics, and the sufficiently high concentra- 
tions in prostatic, seminal fluid, and prostatic ade- 
noma tissue, ciprofloxacin, parenterally administered, 
is well-suited for the therapy of complicated and noso- 
comial urinary tract infections, as well as for bacterial 
prostatitis and perioperative prophylaxis in urologic 
surgery. 
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